Geoffrey I. Shapiro

Brigham and Women's Hospital

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

Compare more Pulmonary and Respiratory Medicine professors.

h-index116
i10-index391
Publications2,054
Citations57,969

Grants

10 total · 4 active

NIH #R01CA307291

Macrophage-directed strategies for BRCA-associated breast cancer

Active
Amount
$700K–$800K
Period
2026-04-10 → 2031-03-31
PIs
3

NIH #P01CA269021

Pathology Core

Active
Amount
$500K–$600K
Period
2024-05-01 → 2029-04-30
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #R01CA285308

Genetically engineered mouse model to improve therapy of NUT carcinoma

Active
Amount
$600K–$700K
Period
2023-09-19 → 2028-08-31
PIs
3

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

10 total · 4 active

NIH #R01CA307291

Macrophage-directed strategies for BRCA-associated breast cancer

Active
Amount
$700K–$800K
Period
2026-04-10 → 2031-03-31
PIs
3

NIH #P01CA269021

Pathology Core

Active
Amount
$500K–$600K
Period
2024-05-01 → 2029-04-30
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #R01CA285308

Genetically engineered mouse model to improve therapy of NUT carcinoma

Active
Amount
$600K–$700K
Period
2023-09-19 → 2028-08-31
PIs
3

NIH #R01CA272982

Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers

Active
Amount
$700K–$800K
Period
2022-09-01 → 2027-08-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P50CA240243

ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)

Amount
$400K–$500K
Period
2020-08-03 → 2025-07-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P50CA168504

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

Amount
$2M–$3M
Period
2013-09-17 → 2024-05-31
PIs
3

Awarded at DANA-FARBER CANCER INST

NIH #UM1CA186709

Dana‐Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Amount
$6M–$7M
Period
2014-03-13 → 2023-02-28
PIs
3

Awarded at DANA-FARBER CANCER INST

NIH #P30CA006516

Program 12: Developmental Therapeutics

Amount
<$100K
Period
1997-03-10 → 2021-11-30
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #R01CA090687

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$300K–$400K
Period
2001-04-01 → 2015-02-28
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P50CA090578

Translational studies of Hsp90 inhibitors in NSCLC

Amount
$100K–$200K
Period
2003-09-19 → —
PIs
1

Awarded at DANA-FARBER CANCER INST

Recent Public Signals

  1. New paper: PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer (Journal of Clinical Investigation)2026-07-07
  2. New NIH award: Macrophage-directed strategies for BRCA-associated breast cancer2026-04-10
  3. New NIH award: Pathology Core2024-05-01

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0002-3331-4095

Professor Insights

Career Trajectory